Organon Launches Ontruzant (biosimilar, trastuzumab) for the Treatment of Gastric Cancer
Shots:
- The company reported the commercial availability of Ontruzant, a biosimilar of Herceptin to treat adults diagnosed with metastatic gastric cancer & other indication
- Organon's collaborator Samsung Bioepis has developed and produced Ontruzant as well as the other biosimilars in its portfolio i.e., Aybintio, Hadlima, Brenzys, and Renflexis
- The company’s goal is to provide more affordable treatment options to the patients to use Ontruzant & continues to support the mission “Here for Her Health"
Ref: Newswire | Image: Organon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
